Physician profile
Daniel J Powers
NPI 1871087940
$466.32
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $352 · 2022: $114.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $66.27 | 2021 | |
| Pfizer INC. | $52.05 | 2021 | |
| Novo Nordisk INC | $50.77 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.19 | 2021-2022 | |
| Esperion Therapeutics, INC. | $28.64 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $23.74 | 2021 | |
| Mayne Pharma Commercial LLC | $23.05 | 2022 | |
| Genentech USA, INC. | $19.34 | 2021 | |
| Supernus Pharmaceuticals, INC. | $18.01 | 2022 | |
| Gilead Sciences, INC. | $17.41 | 2021 | |
| Alkermes, INC. | $16.64 | 2021 | |
| Amgen INC. | $16.19 | 2022 | |
| Amarin Pharma, INC. | $16.12 | 2021 | |
| Currax Pharmaceuticals LLC | $15.37 | 2021 | |
| Amneal Pharmaceuticals LLC | $14.86 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Adlon Therapeutics L.P. | $14.30 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $14.02 | 2021 | |
| Lilly USA, LLC | $13.55 | 2022 | |
| Bausch Health US, LLC | $12.80 | 2022 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Powers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.